CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ...
THIO combined with Libtayo shows improved progression-free survival of 5.6 months versus 2.5 months with standard treatments in advanced non-small cell lung cancer. The THIO-101 trial indicates a ...
The positive outcomes reported in our publication show THIO’s potential as a new therapeutic approach,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. “THIO already holds Orphan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results